Advertisement

European Journal of Clinical Pharmacology

, Volume 75, Issue 1, pp 135–136 | Cite as

Tamoxifen administration and the risk of Parkinsonism

  • François Montastruc
  • Farzin Khosrow-Khavar
  • Agnès Sommet
  • Christel Renoux
  • Jean-Louis MontastrucEmail author
Letter to the Editor

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Lai SW (2018) Tamoxifen administration and risk of Parkinson’s disease. Eur J Clin Pharmacol.  https://doi.org/10.1007/s00228-018-2553-y
  2. 2.
    Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL (2018) Tamoxifen and the risk of parkinsonism: a case/non-case study. Eur J Clin Pharmacol 74:1181–1184CrossRefGoogle Scholar
  3. 3.
    Latourelle JC, Dybdahl M, Destefano AL, Myers RH, Lash TL (2010) Risk of Parkinson's disease after tamoxifen treatment. BMC Neurol 10:23CrossRefGoogle Scholar
  4. 4.
    Lin HF, Liao KF, Chang CM, Lin CL, Lai SW (2018) Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan. Eur J Clin Pharmacol 74:99–107CrossRefGoogle Scholar
  5. 5.
    Hong CT, Chan L, Hu CJ, Lin CM, Hsu CY, Lin MC (2017) Tamoxifen and the risk of Parkinson’s disease in female patients with breast cancer in Asian people: a nationwide population-based study. J Breast Cancer 20:356–360CrossRefGoogle Scholar
  6. 6.
    Faillie JL, Montastruc F, Montastruc JL, Pariente A (2016) Pharmacoepidemiology and its input to pharmacovigilance. Therapie 71:211–216CrossRefGoogle Scholar
  7. 7.
    Faillie JL (2018) Case-non case studies: principles, methods, bias and interpretation. Therapie 73:247–255CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Service de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmacoépidémiologie et d’Informations sur le Médicament, CIC INSERM 1436, NeuroToul Centre of Excellence in Neurodegeneration, INSERM UMR 1027Faculté de Médecine de l’Université de Toulouse and Centre Hospitalier Universitaire de ToulouseToulouseFrance
  2. 2.Department of Epidemiology, Biostatistics, and Occupational Health, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General HospitalMcGill UniversityMontrealCanada
  3. 3.Department of Neurology and NeurosurgeryMcGill UniversityMontrealCanada

Personalised recommendations